Press release
Glioblastoma Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight
Glioblastoma Treatment Market
(Albany, USA) DelveInsight's "Glioblastoma Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The Glioblastoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Glioblastoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Glioblastoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Glioblastoma market.
Key Takeaways from the Glioblastoma Market Report
* The increase in Glioblastoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Glioblastoma Market is anticipated to witness growth at a considerable CAGR.
* The leading Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.
* Promising Glioblastoma Pipeline Therapies in the various stages of development include ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
* On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). LP-184 induces tumor cell death through DNA damage and is currently in a Phase 1a trial assessing its safety and tolerability in patients with various solid tumors, including GBM. The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.
* April 2024:- Boston Scientific Corporation- FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM. Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight here
News-ID: 3806116 • Views: …
More Releases from ABNewswire
Oral Surgeon Huntington Beach Practice Elevates Standards for Patient Comfort an …
Huntington Beach oral surgery practice, The Wisdom Teeth Guru sets new patient care standards through specialized training, advanced sedation options, and efficient same-day treatment capabilities under Dr. Kiet Tran's leadership.
A Huntington Beach dental practice has gained recognition for transforming how patients experience oral surgery procedures. The Wisdom Teeth Guru [https://www.google.com/maps/place/The+Wisdom+Teeth+Guru/data=!4m2!3m1!1s0x0:0x98592ab69d239d3a?sa=X&ved=1t:2428&hl=en&ictx=111], led by Dr. Kiet Tran, has established new benchmarks in patient care through advanced techniques and a commitment to making…
Columbus Moving Services Expands as Moving Ahead Services Responds to Central Oh …
Moving Ahead Services expands coverage across 23 Central Ohio communities, offering flexible moving solutions with regulatory compliance and community partnerships that support both residential and commercial relocations.
The Central Ohio region continues to experience steady population growth, and Moving Ahead Services has positioned itself to address the increasing demand for professional relocation assistance. The expansion of Columbus moving services reflects the company's two decades of experience serving the area, with operations…
What Does a Full-Service Move Include? Moving Companies Report Surge in Demand f …
Greenville homeowners increasingly prefer comprehensive relocation packages that handle packing, furniture assembly, transportation, and setup. Professional services reduce stress and damage while streamlining transitions.
Homeowners and renters across Greenville are opting for comprehensive relocation packages as the complexity of modern moves continues to grow. Recent trends show that families and businesses alike are seeking moving companies for an end-to-end solution that eliminates the stress traditionally associated with changing addresses. This shift…
Local Garage Door Company Sees Surge in Emergency Repairs Following Extreme Temp …
AA Garage Door LLC reports increased emergency repairs across St. Paul as extreme cold causes cable failures and spring breaks. Technicians respond to urgent service needs throughout Twin Cities neighborhoods affected by harsh winter conditions.
Recent weather patterns across the St. Paul region have created unprecedented challenges for homeowners, with plummeting temperatures causing significant strain on residential overhead door systems. AA Garage Door LLC, a trusted garage door company [https://maps.google.com/maps?ll=44.91738,-93.190993&z=16&t=h&hl=en&gl=PH&mapclient=embed&cid=15111651982362415047&q=garage+door+company&oq=garage+door+company+near+me] serving…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
